Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation

• Main Authors: Ştefan Cristian Vesa, Sonia Irina Vlaicu, Sorin Crișan, Octavia Sabin, George Saraci, Vitalie Văcăraș, Daciana Elena Popa, Paula Pârcălab, Valer Ioan Donca, Antonia Eugenia Macarie, Madalina Sava, Anca Dana Buzoianu
• Format: Article
• Language: English
• Published: MDPI AG 2020-10-01
• Series: Healthcare
• Subjects: atrial fibrillation; deep vein thrombosis; anticoagulant choice; direct oral anticoagulants; vitamin K antagonists
• Online Access: https://www.mdpi.com/2227-9032/8/4/404

(1) Aim: The aim of this study was to assess the preferences of oral anticoagulants (OA) in patients diagnosed with deep vein thrombosis (DVT) of lower limbs or non-valvular atrial fibrillation (AF) requiring anticoagulation for medium/long term. (2) Materials and methods: the study included consecutive patients admitted with a diagnosis of either acute DVT of lower limbs (without signs of pulmonary embolism) or non-valvular AF who required oral anticoagulation, in a time frame of 18 months from January 2017 until June 2018. The following data were recorded: demographic variables, comorbidities (ischemic heart disease, arterial hypertension, heart failure, stroke, peripheral artery disease, diabetes mellitus, obesity), type and dose of OA (acenocoumarol, dabigatran, apixaban, rivaroxaban), complications due to the use of OA. (3) Results: AF patients were older and had considerably more cardiovascular comorbidities than DVT patients. Vitamin K antagonists (VKA) were more likely to be administered in patients with AF, as they had indication for indefinite anticoagulation. VKA were more frequently prescribed in patients with ischemic heart disease, heart failure, and diabetes compared with DVT patients. Moreover, complications related to OA use were more frequent in the VKA group. Almost half of patients with acute DVT (48.5%) were treated with direct OA (DOAC) rather than VKA, and only a quarter of AF patients (24.8%) were treated with DOACs.